Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
2018 · New England Journal of Medicine · 651 citations
https://doi.org/10.1056/nejmoa1803164
M
Marc Debled
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
252
Papers
8.1K
Citations
42
h-index
93
i10-index
Marc Debled is an academic researcher from Université de Bordeaux. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology. The author has an h-index of 42, co-authored 215 publications.
Papers by this author
works6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013 · The Lancet Oncology · 337 citations
https://doi.org/10.1016/s1470-2045(13)70225-0
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
2019 · British Journal of Cancer · 210 citations
https://doi.org/10.1038/s41416-019-0619-y
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
2015 · Journal of Clinical Oncology · 195 citations
https://doi.org/10.1200/jco.2015.60.8133
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
2011 · Annals of Oncology · 159 citations
https://doi.org/10.1093/annonc/mdr051
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
2021 · ESMO Open · 127 citations
https://doi.org/10.1016/j.esmoop.2021.100114
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat